To address the functional consequences of BRAF V600E mutations in PXA, we assessed MAPK pathway activation by measuring levels of phospho-p44/42 MAPK (Erk1/2) by IHC. The gene discussed is BRAF; the disease is pleomorphic xanthoastrocytoma.